Dr. Farhad Rahimi Danesh, MD

Dr. Danesh practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Danesh's NPI, 1740312412, was assigned on March 9, 2007. Dr. Danesh graduated from Universidad de Salamanca in 1989. Dr. Danesh's Texas license number on file is N1843.

Dr. Danesh's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Danesh's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Danesh practices. Vendor and product names are available with a free account.

Nephrology is Dr. Danesh's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Danesh is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Danesh's licenses on file in 11 states: Texas, Florida, Arizona, Oklahoma, Tennessee, Washington, Alabama, Georgia, Louisiana, Mississippi and Illinois.

Dmand AI lists acute kidney failure, chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Danesh treats.

CMS data shows 263 Medicare services from Dr. Danesh across 7 procedure codes in 2024, for 139 Medicare patients. Medicare paid $23,312 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 139 Medicare patients who saw Dr. Danesh in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 12% are also on Medicaid. Their average risk score is 4.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Danesh's median patient age at 69, with 51% women.

In 2018, Dr. Danesh wrote 66 Medicare Part D claims. They cover 3 drugs, with $1,109 in total drug cost. In 2017, CMS named 58 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Danesh for performance year 2024, reported as part of a group. Dr. Danesh accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Danesh as offering telehealth.

Dmand AI links 31 papers to Dr. Danesh, published from 2002 to 2024. 2019 was the busiest year, with 4. The most frequent topics are Diabetic Nephropathies, Kidney and MicroRNAs. Dr. Danesh has published most often in Kidney Int. Dr. Danesh's most frequent co-authors are Motoo Araki, MD, Morie A. Gertz, MD and Rajesh Sharma, MD.

CMS Open Payments shows 50 general payments to Dr. Danesh from 16 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 62% of the total. Daiichi Sankyo Company LTD paid the most, $14,205.

Dmand AI lists 1 award for Dr. Danesh, most recently CMS Stage 1 EHR in 2012.

Dr. Danesh graduated from Universidad de Salamanca in 1989.

Dr. Danesh is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.